Rocket Pharmaceuticals (RCKT) Gains from Investment Securities (2014 - 2024)

Rocket Pharmaceuticals (RCKT) posted Gains from Investment Securities of -$1000.0 for Q4 2024, up 99.04% sequentially from -$104000.0 in Q3 2024.

Analysis

Rocket Pharmaceuticals (RCKT) Gains from Investment Securities (2014 - 2024) Analysis & Trends

Rocket Pharmaceuticals has reported Gains from Investment Securities for 3 years, with the latest figure at -$1000.0 in Q4 2024.

Quarterly Gains from Investment Securities changed N/A year-over-year to -$1000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$1000.0 (up 99.95% YoY) and the FY2024 annual result came in at -$1.9 million, down 415.38% from the prior year.
Gains from Investment Securities rose to -$1000.0 in Q4 2024 per RCKT's latest filing, from -$104000.0 in the prior quarter.
Over five years, Gains from Investment Securities peaked at $1.1 million in Q1 2024 and troughed at -$2.9 million in Q2 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Rocket Pharmaceuticals	437.27 Mn	437.27 Mn	-

Historic Data

Download Data